Strategic focus Therapeutics company focusing on novel ketamine analogs for neuropsychiatric disorders, presenting opportunities to engage in partnerships, licensing discussions, or co-development arrangements around treatment resistant depression, PTSD, and OCD.

Boardroom signals Recent board appointments and governance updates indicate active leadership engagement and potential for strategic partnerships or investor-driven collaborations; reach out to key decision makers introduced by board connections.

Clinical collaboration Existing research and license agreements with major pharma (Janssen) suggest openness to external collaboration; sales outreach could target joint development, research collaborations, or licensing discussions for Amorsa’s ketamine analog pipeline.

Financial foothold Revenue in the lower multi-million range with a lean platform (employee base listed as 0-1) implies high potential for scalable clinical programs; approach with value-focused partnerships, co-funding, or milestone-driven deals to de-risk investment.

Tech and web presence Small technology stack and focused web presence indicate early-stage commercialization; leverage digital channels to initiate outreach, establish thought leadership, and coordinate low-friction pilot opportunities or sponsored research.